Text Size: a  |   a 

MS Trials Have Found More Success Than Other Diseases

January 5, 2016

An analysis published in Multiple Sclerosis and Related Disorders states that clinical trials for multiple sclerosis therapies demonstrate a success rate that is triple that of other diseases. This makes sense, because over the last 20 years, there has been a rapid increase in the number of available MS disease modifying therapies.

“MS is a ‘best in class' disease area relative to other disease conditions when you look at the number of new drug approvals that have taken place and the fact that many represent very different mechanisms of action,” Jayson Parker, PhD, assistant professor at the University of Toronto Mississauga, told Neurology Advisor. “Within neurology this is simply not the case for conditions such as Alzheimer's disease, depression, or Parkinson's disease.”

Of the 53 distinct compounds that met inclusion criteria, 25 trials progressed and 5 compounds were FDA approved for MS during the study period. In all trial phases, MS clinical trials had a 27% success rate compared to an industry rate of 10%.

Dr. Parker continued, “Our results suggest this prior approval history does not mitigate the risk of clinical trial failure. On the contrary, new drugs without any prior FDA approval history seem to carry less clinical trial risk in MS. Physicians should continue to embrace novel drugs with new mechanisms of action in this condition.”